美国食品药品监督管理局确认, 伊利利利解决了Mounjaro和Zepbound的短缺问题, FDA confirms Eli Lilly resolves Mounjaro and Zepbound shortage, investing in manufacturing capacity.

根据美国食品和药物管理局的说法, 伊利利利公司的减肥和糖尿病药物Mounjaro和Zepbound已经不再短缺了. Eli Lilly's weight-loss and diabetes medications, Mounjaro and Zepbound, are no longer in shortage, according to the FDA. 该公司通过投资数十亿美元制造能力来解决供应问题。 The company has resolved supply issues by investing billions in manufacturing capacity. 虽然现在可以满足国家需求,但局部供应中断仍然可能发生。 While national demand can now be met, localized supply disruptions may still occur. 林业发展局警告说,在短缺期间出现的这些药物的复合版本未经林业发展局批准,可能缺乏严格的安全测试。 The FDA warns that compounded versions of these drugs, which emerged during the shortage, are not FDA-approved and may lack rigorous safety testing.